N/A N=182 Less Infections for the Diabetic Foot
Diabetic Foot
Primary: Number of Participants Experiencing Clinical Failure — 26; 30 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections
Diabetic Foot Infections
Primary: Clinical Success (in ITT Population) — 95.7 percentage of participants
Phase 2 N=175 Preventing Diabetic Foot Ulcers Through Cleaner Feet
Diabetic Foot Ulcer
Primary: Time to New Foot Complication Among All Randomized Participants — 12; 14 Participants
Phase 2 N=56 The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers
Diabetic Foot Ulcer
Primary: Number of Participants With a Clinical Cure at Visit 3 (Day 7) — 0; 3 Participants
Phase 3 N=189 Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
Diabetic Foot Infection
Primary: Number of Participants With Clinical Response — 43; 63 Participants
Phase 3 N=200 Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
Diabetic Foot Infection
Primary: Number of Participants With Clinical Response — 56; 54 Participants
Phase 3 N=612 Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers
Foot Ulcer, Diabetic · Infection
Primary: Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection) — 115; 64; 48 Participants
Phase 2 N=70 Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer
Diabetic Foot Ulcer
Primary: Number of Participants With a Clinical Outcome of "Clinical Cure" — 14; 7 Participants
Phase 3 N=524 Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers
Foot Ulcer, Diabetic · Infection
Primary: Percent of Patients With a Clinical Outcome of Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection) — 69; 41; 36 percentage of subjects
Phase 3 N=68 Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Biopsies — 2.46; 2.64; 2.56; 2.07 UI/dL
Phase 4 N=88 Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection
Diabetic Foot Ulcer
Primary: Clinical Cure — 38; 39 participants
N/A N=20 CO2-Laser Treatment in Patients With Diabetic Infected Foot Ulcers
Diabetic Foot Ulcer
Primary: Bacterial Load — -99.9; -50.0 Percent change from baseline
Phase 3 N=1,061 Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.
Bacterial Infections · Diabetic Foot · Osteomyelitis
Primary: Number of Patients With Clinical Response of Cure Vs. Failure. — 316; 334; 92; 71 patients
Phase 3 N=130 Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Number of 100% Wound Closure — 55.74; 50.82 percentage of patients
Phase 2 N=30 Micro-mobile Foot Compression and Diabetic Foot
Diabetes · PAD · Lower Extremity Edema
Primary: Change in Balance From Baseline to 4 Weeks — 0.94; 0.76 cm
Phase 2 N=16 Novel Offloading for Diabetic Foot Ulcers With PulseFlow: A Prospective Study
Diabetic Foot Ulcer · Offloading
Primary: Lower Extremity Perfusion Change From Baseline to 4 Weeks — 167; 75 percentage of baseline perfusion
N/A N=148 Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers
Diabetic Foot Ulcer · Ulcer Foot · Diabetic Foot
Primary: Complete Wound Healing — 32; 16; 32; 16 Participants — p=0.007
N/A N=39 Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Size of Index Wound Based on Calculations Wound Width x Length x Depth 2. Size of Index Wound Based on Calculations Wound Width x Length x Depth — 2.05; 3.33 mm^3
N/A N=24 Extracorporeal Shockwave Therapy for Diabetic Foot Wounds
Diabetic Foot · Wound
Primary: Wound Volume — 1.16 cm^3
Phase 4 N=17 Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Wound Appearance — 19; 19; 16.9; 14.5 units on a scale
N/A N=23 Continuous Diffusion of Oxygen (CDO) Treatment for Healing of Diabetic Foot Ulcers
Foot Ulcer, Diabetic
Primary: Tissue Oxygenation as Measured by Hyperspectral Imaging — 63.58; 61.91; 76.33; 77.55 percent concentration of oxyhemoglobin
Phase 4 N=106 DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes
Chronic Foot Ulcers
Primary: Full Epithelialization of the Wound — 16; 8 participants — p=<0.05
Phase 2 N=30 Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus
Diabetic Foot Infections
Primary: Number of Participants With Treatment-related Treatment-emergent Adverse Events as Graded According to the Common Terminology Criteria for Adverse Events v4.02 (CTCAE)…
N/A N=91 Intensive Insulin Treatment and Ischemic Foot Ulcer
Ischemic Foot Ulcer
Primary: Ischemic Foot Ulcer — 3; 10 participants
N/A N=225 Instant Total Contact Cast to Heal Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Number of Participants Who Achieve Full Wound Healing. — 35; 63; 37 Participants
N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Phase 2 N=15 Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients
Diabetes · Infection
Primary: Efficacy of Timentin Delivered by PILP Procedure (Treatment Group) Versus Intravenous Delivery (Control Group) at Reducing Microbiological Load in Subjects With…
Phase 4 N=102 Use of Santyl in Diabetic Foot Ulcers
Diabetic Foot · Foot Ulcer, Diabetic
Primary: Mean Percent Change in Ulcer Area From Baseline to the End of the Treatment. — 57.6; 41.3 percentage of change from baseline (cm2)
N/A N=8 ULCERS - Electrical Stimulation in Diabetic Foot Ulceration
Diabetes
Primary: Number of Day Until 50% Healing of Leg Ulcer — 55; 30 Days
Phase 3 N=276 Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients
Diabetic Foot Ulcer
Primary: Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing — 68; 31; 23; 14 participants